Tirzepatide: Peptide Profile, CAS & Properties
CAS 2023788-19-2 · 4813.53 g/mol
Tirzepatide (CAS 2023788-19-2) is a synthetic 39-amino-acid acylated GIP/GLP-1 dual receptor agonist studied for type 2 diabetes and obesity. It belongs to the incretin multi-agonist class and is approved as an active ingredient by the US FDA and EMA. This page provides reference information on Tirzepatide.
- CAS Number
- 2023788-19-2
- Molecular Formula
- C225H348N48O68
- Molecular Weight
- 4813.53 g/mol
- Drug Class
- GIP / GLP-1 dual receptor agonist
What is Tirzepatide?
Tirzepatide is a long-acting dual incretin receptor agonist — a single 39-amino-acid peptide engineered to activate both the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. The backbone carries two α-aminoisobutyric acid (Aib) substitutions and is acylated at a lysine residue with a C20 fatty di-acid through a γGlu linker, conferring strong albumin binding, resistance to DPP-4 degradation and a C-terminal amide — properties that support once-weekly dosing.
With CAS number 2023788-19-2, molecular formula C225H348N48O68 and a molecular weight of approximately 4813.53 g/mol, tirzepatide is typically handled as a lyophilised powder. It is approved as an active ingredient by the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management) and by the EMA (2022 for type 2 diabetes).
How Tirzepatide Is Produced & Characterised
Tirzepatide is a synthetically demanding acylated peptide: the 39-mer length, the two Aib residues and the C20 fatty di-acid conjugation all create opportunities for deletion sequences, diastereomers and incomplete acylation. In industry practice, peptides of this class are produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled lipid side-chain conjugation, followed by preparative dynamic axial compression (DAC) HPLC purification that isolates the target sequence from closely related impurities. The purified material is typically lyophilised to a stable, uniform powder.
Characterisation generally combines UPLC/HPLC for purity determination with LC-MS to confirm the sequence and profile minor structural variants. Counter-ion (acetate) content, water content, residual solvents and peptide content are commonly measured so the molecule's identity, strength and impurity profile are fully described.
Typical Quality Specifications & Impurity Profile
Reference-grade tirzepatide is commonly described against a defined specification. Purity for pharmaceutical-grade material is typically reported at ≥99.0% by UPLC/HPLC, with individual impurities controlled below roughly 0.10%, and the sequence and related substances confirmed by LC-MS impurity profiling.
Analytical methods used to characterise such peptides are generally validated to ICH Q2(R1), and stability behaviour is described using ICH Q1A(R2) long-term and accelerated data. Typical physical attributes include a white to off-white lyophilised appearance and storage at low temperature, protected from light and moisture.
Regulatory & Approval Context
Tirzepatide is approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management) and the EMA (2022 for type 2 diabetes). As an approved molecule, its chemistry, manufacturing and controls (CMC) are documented within regulatory frameworks such as the CTD, and analytical and stability data are characterised to support the molecule's regulated status.
This reference page summarises the molecule's properties, structure and approval context for educational purposes. WinHyCare does not supply tirzepatide; among incretin peptides, WinHyCare supplies Semaglutide.
Tirzepatide API — Specifications
| Compound | Tirzepatide |
|---|---|
| CAS Number | 2023788-19-2 |
| Molecular Formula | C225H348N48O68 |
| Molecular Weight | 4813.53 g/mol |
| Sequence | 39 amino acids, acylated (C20 di-acid side chain), C-terminal amide |
| Drug Class | GIP / GLP-1 dual receptor agonist |
| Appearance | White to off-white lyophilised powder |
| Typical Purity (HPLC) | ≥ 99.0% (single impurity < 0.10%) |
| Synthesis Route | Fmoc SPPS + DAC prep-HPLC purification |
| Regulatory Status | Approved active ingredient (US FDA 2022/2023; EMA 2022) |
| Form | Lyophilised powder |
| Storage | Store at -20°C, protected from light & moisture |
Reference data only — WinHyCare neither supplies nor manufactures this compound; see our Semaglutide API for the product we supply. Regulatory status: Approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes; 2023 for chronic weight management) and the EMA (2022 for type 2 diabetes).
Tirzepatide API — Frequently Asked Questions
What is Tirzepatide?
Tirzepatide is a synthetic, long-acting peptide that acts as a dual agonist at both the GIP and GLP-1 receptors. It is a single 39-amino-acid chain acylated with a C20 fatty di-acid side chain and carrying a C-terminal amide, designed for once-weekly administration.
What is its CAS number and molecular weight?
Tirzepatide's CAS number is 2023788-19-2, its molecular formula is C225H348N48O68, and its molecular weight is approximately 4813.53 g/mol.
Is Tirzepatide approved?
Yes. Tirzepatide is approved as an active ingredient by major regulators including the US FDA (2022 for type 2 diabetes and 2023 for chronic weight management) and the EMA (2022 for type 2 diabetes).
What class of peptide is Tirzepatide?
Tirzepatide belongs to the GLP-1 and incretin multi-agonist class. Specifically, it is a GIP / GLP-1 dual receptor agonist — a single peptide that activates two incretin receptors.
What is Tirzepatide being studied or used for?
Tirzepatide is indicated for type 2 diabetes and chronic weight management (obesity), reflecting its dual incretin receptor activity on glucose regulation and body weight.
How is Tirzepatide produced and characterised?
Peptides of this class are generally produced by Fmoc solid-phase peptide synthesis (SPPS) with controlled lipid side-chain conjugation, followed by preparative HPLC purification and lyophilisation. Identity and purity are typically confirmed by UPLC/HPLC and LC-MS impurity profiling.
Related Peptide APIs
Semaglutide API
CAS 910463-68-2
GLP-1 & Incretin Multi-AgonistsRetatrutide API
CAS 2381089-83-2
Amylin & Co-AgonistsCagrilintide API
CAS 1415456-99-3
GLP-1 & Incretin Multi-AgonistsMazdutide API
CAS 2259884-03-0
Technical Reference Page
WinHyCare neither supplies nor manufactures Tirzepatide; this page is provided as a technical reference. The peptide API we supply is Semaglutide.